



Regulatory Inspector Quick Reference Guide




T R I A L INTERACTIVE

Logging in and Navigating to the Study Room

- 1. Log in with your Username and Password.
 - a. Warning: After five failed attempts, you will be temporarily locked out.
- 2. On the Home Page you will see a list of rooms to which you have access. If no rooms appear, please select *All* from the menu at the top.
- 3. Click on the name of a room to enter.


How to Audit Documents

- 1. If necessary, click on the blue drop-down menu
- above the index to select the appropriate audit. (sample audit and folder names shown)




2. The documents can be displayed in several ways. Pick your preferred viewing options from the drop-down menu above the index.

This document is proprietary and is protected by U.S. and international copyright laws and trade secret laws. Copyright © 2020 TransPerfect International, Inc. (TransPerfect). All rights reserved. No part of this document may be reproduced, copied, adapted, modified, distributed, transferred, translated, disclosed, displayed or otherwise used by anyone in any form or by any means without the express written authorization of TransPerfect Senior Management and/or Product Management. Other names may be trademarks of their respective owners.





May 2020 Page 2 of 3



4. Select a line item and click **Document View** to open a document and associated metadata from the grid.

5. Examine to determine if it meets the audit criteria.

Document 🔻 🔸 Export 👻 🖺 Assign To				R Ade	d to Cart 🛛 🗮 Documents Cart 🛛 🝷 🖬 Layout 👻
Quality Review 2nd Quarter Quality R Document Status Pending View by Index			★ Add to Favorites ● My 0	Comment	🖋 Expand Metadata Audit Queries
Search by folder na 🗢 🚥 💌					United States_IPInventDoc_20180911
🔻 🞥 Customize your Index name	56				Audit —
	Pharmaceuticals,	ATIENT INVESTIGATIONAL P	led Duration Trial PRODUCT ACCOUNTABILITY RECORD	Protocol: 11-019	Status *
Staging 3	Patient #: 800045001	Patient #: 900045001 Patient Initials: V.C. Site #: 045			This field is required
Rejected Documents 1	Country: LATVIA Investigator Name#:				Comments
	Kit # Quantity Dispensed (# capsules)	dd/mmm/yyyy) Patient By R (Initials)	Quantity letuned by Patient Quantity Used by Patient Date Returned Patient (# capsules) (dd/mmm/yyyy)	Received by (Initials) (MonIFed by (MonIfed by anorests and anorests	Contains PHI? 😧
	100100	40ct 1012 1.S.	14 36 27. NOV 2012	J.S. Dinne	Grading/Finding
	50				Critical
	50				Major
	50				Minor
	50			Man and a contract of	Responsible Party
	Comments				· · · · · · · · · · · · · · · · · · ·
					Responder 🚱
		5. 1975 1973 N		Page_of_	· · · · · · · · · · · · · · · · · · ·
c	11-019_Drug Accountability Reco	ordsV1.2 March2012			Cancel Save Save & Next
	Grid View	Document View		88	Previous Document Of 1 Next Document

6. Choose a **Status** and other applicable options, e.g. Comments that will remain with the audit history.

7. click Save or Save and Next

This document is proprietary and is protected by U.S. and international copyright laws and trade secret laws. Copyright © 2020 TransPerfect International, Inc. (TransPerfect). All rights reserved. No part of this document may be reproduced, copied, adapted, modified, distributed, transferred, translated, disclosed, displayed or otherwise used by anyone in any form or by any means without the express written authorization of TransPerfect Senior Management and/or Product Management. Other names may be trademarks of their respective owners.